Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Repligen Corp

NASDAQ: RGEN · Life Sciences · 7 alerts · CIK 730272

Share price
$162.78Close, Nov 16
Market cap
$10.4B
Shares outstanding
63.92MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Repligen Corp filings on SEC EDGAR ↗

9:14 AM ET 8-K
M&A Deal

Repligen M&A Deal with BioLife Solutions, Inc.

Repligen Corporation completed its acquisition of BioLife Solutions, Inc., a developer of cell processing tools for the cell and gene therapy market. Under the terms of the merger, BioLife stockholders received $11.25 in cash and 0.1442 shares of Repligen common stock for each share held. The deal expands Repligen's presence in the cell therapy workflow by adding BioLife's biopreservation media portfolio, including the CryoStor product line.

Counterparty
BioLife Solutions, Inc.

“BioLife’s highly-differentiated portfolio of products expands our presence in the rapidly growing cell therapy market, adding a deeply embedded, high-margin consumables business with attractive recurring revenue. Together, we are better positioned to support customers across critical stages of the cell therapy workflow and help advance the development and commercialization of next-generation therapies.”

Olivier Loeillot, President and Chief Executive Officer of Repligen

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.